Completion of the clinical phase of the monocentric, prospective, open label pilot study conducted in France of daily dosing of IMA001 in 12 sickle cell disease patients.
Imalia Reports Initial Proof-of-Concept Data for IMA001 in Sickle Cell Disease Model
Imalia reports initial proof-of-concept data for the effect of IMA001,on the progression of markers